← Back to Search

Other

Usual Care for Staphylococcus aureus Bacteremia

N/A

Recruiting

Led By Matthew Semler, MD, MSc

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinician has ordered intravenous vancomycin

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 14 days

Awards & highlights

Study Summary

This trial will compare the use of a rapid diagnostic test called the T2Bacteria® Panel with the standard method of using blood cultures to identify bacterial infections in patients who are suspected to have an infection

Who is the study for?

Adults over 18 who are in the Emergency Department at Vanderbilt University Hospital, have been given intravenous vancomycin, and had blood cultures ordered within 12 hours of arriving. The trial is for those suspected to have a bacterial bloodstream infection.Check my eligibility

What is being tested?

The study compares the T2Bacteria Panel, which tests directly from blood for bacteria, with usual care using blood cultures that take longer to show results. It aims to see if this rapid test can improve antibiotic use and patient outcomes.See study design

What are the potential side effects?

While not explicitly stated here, potential side effects may relate to unnecessary exposure to broad-spectrum antibiotics like vancomycin such as kidney damage or hearing issues due to toxicity and increased risk of antimicrobial resistance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My doctor has prescribed IV vancomycin for me.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Time to last dose of intravenous vancomycin

Secondary outcome measures

Time to last dose of systemic anti-pseudomonal beta-lactam antibiotic

Trial Design

2Treatment groups

Active Control

Group I: Usual CareActive Control1 Intervention

Patients will receive blood cultures and will not receive direct-from-blood testing.

Group II: Direct-from-blood testingActive Control1 Intervention

In addition to usual care, patients will receive direct-from-blood testing using the T2Bacteria® Panel.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

863 Previous Clinical Trials

672,509 Total Patients Enrolled

Matthew Semler, MD, MScPrincipal InvestigatorVanderbilt University Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are potential participants currently able to apply for enrollment in this trial?

"According to information available on clinicaltrials.gov, this ongoing clinical trial is actively seeking eligible participants. The study was initially posted for public access on December 13th, 2023 and received its most recent update on December 15th, 2023."

Answered by AI

What is the current number of participants being admitted into this research trial?

"Indeed, as per the information available on clinicaltrials.gov, this study is currently seeking eligible participants. The trial was initially posted on December 13th, 2023 and was last updated on December 15th, 2023. Researchers aim to recruit a total of 500 patients from a single designated location."

Answered by AI

Recent research and studies

Intensive Care MedicineJournal

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

Rhodes, Andrew, Laura E. Evans, Waleed Alhazzani, Mitchell M. Levy, Massimo Antonelli, Ricard Ferrer, Anand Kumar, et al.. 2017. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016”. Intensive Care Medicine. Springer Science and Business Media LLC. doi:10.1007/s00134-017-4683-6.

clinicaltrials.govStudy

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

Matthew Semler 2023. "Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06069206.

All > Sepsis